Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AfaBev-CS
jRCTs061180006Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Afatinib + bevacizumab with Afatinib monotherapy (2 arms). Primary endpoint: progression-free survival. Started Aug 2017; status: completed.
02
Drugs
afatinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061180006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180006.